Reset filter
Mots-clés
D016430 ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
    1. 7.1. Anesthésie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Gériatrie
    1. 7.5. Gynécologie/obstétrique
    1. 7.6. Médecine interne
      1. Hématologie
      1. Infectiologie
      1. Cardiologie/angiologie
      1. Pneumologie
      1. Gastroentérologie
      1. Néphrologie
      1. Endocrinologie/métabolisme
      1. Rhumatologie
    1. 7.7. Neurologie
    1. 7.8. Ophtalmologie
    1. 7.9. Médecine palliative
    1. 7.10. Pathologie/médécine légale
    1. 7.11. Pédiatrie
    1. 7.12. Psychiatrie/psychosomatique
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Chirurgie générale/viscérale
      1. Neurochirurgie
      1. Chirurgie plastique
      1. Chirurgie cardiaque/thoracique
      1. Chirurgie traumatologique/orthopédie
      1. Chirurgie vasculaire
    1. 7.15. Urologie
    1. 7.16. Médecine dentaire/MKG
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

66 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Recurring cancer children (ADVL0212 NCT00053963) - Reporting Period Worksheet cancer (NCT00053963)

- 22/03/2015 - 1 Formulaire, 5 Groupes Item, 58 Eléments de données, 1 Langue
Groupes Item: Header, Patient characteristics, Concomitant Medication, Patient status, Adverse event
ADVL0212: Reporting Period Worksheet FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1EC15B1-1989-311F-E034-0003BA12F5E7

Pharmacokinetic Study of Doxorubicin in Children With Cancer DRKS00003787 NCT01095926 - 1st Sampling period

- 27/09/2021 - 2 Formulaires, 20 Groupes Item, 113 Eléments de données, 1 Langue
Groupes Item: Physical Examination, Determination of cardiac function (before sampling period), Clinical chemistry, Haematology, Agents that are known to interact with doxorubicin according to SmPCs administered?, Antiemetic agents administered?, Cardioprotective agents administered?, Systemic antimycotic agents, Other agents administered?, Actual protocol block, Start of actual protocol block, Chemotherapy in actual protocol block administered ?, Previous anthracycline treatment, Doxorubicin treatment in 1st sampling period, Haematological toxicity of actual protocol block, Transfusions, Determination of cardiac function (end of sampling period), Adverse events, Start of next protocol block, Footer module
Official Title: Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity. https://clinicaltrials.gov/ct2/show/NCT01095926 NCT01095926

Registration

6 Groupes Item 25 Eléments de données

Refractory tumors in children (NCT00053963) - Eligibility Worksheet (ADVL0212 NCT00053963)

- 20/03/2015 - 1 Formulaire, 2 Groupes Item, 32 Eléments de données, 1 Langue
Groupes Item: Header, Eligibility criteria
ADVL0212: Eligibility Worksheet FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1EC07E8-6588-30D1-E034-0003BA12F5E7

Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314 - Therapy and toxicity cycle 10-13

- 20/09/2021 - 16 Formulaires, 16 Groupes Item, 68 Eléments de données, 1 Langue
Groupes Item: Therapy cycle 10-13, Therapy after cycle, Propranolol, Propranolol therapy deviation, Celecoxib, Celecoxib deviation, Cyclophosphamide, Cyclophosphamide deviation, Vinblastine, Vinblastine deviation, Toxicity overview, Toxicity, Hospitalization, Comments, Transfusion, Footer module
NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln

Therapy and toxicity cycle > 13

16 Groupes Item 68 Eléments de données

Therapy and toxicity cycle 1-3

16 Groupes Item 68 Eléments de données

Therapy and toxicity cycle 4-6

16 Groupes Item 68 Eléments de données

Therapy and toxicity cycle 7-9

16 Groupes Item 68 Eléments de données

Baseline

13 Groupes Item 77 Eléments de données

Reference

12 Groupes Item 111 Eléments de données

Protocol IIIA AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Protocol IIIA AIEOP-BFM ALL 2009 NCT01117441

- 21/05/2016 - 1 Formulaire, 4 Groupes Item, 32 Eléments de données, 1 Langue
Groupes Item: Patient Information, Chemotherapy Regimen, PEG-L-ASP/ Erwinase, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Study Protocol IIIA. Clinical Trial Number: NCT01117441.

Protocol IB AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Protocol IB AIEOP-BFM ALL 2009 NCT01117441

- 21/05/2016 - 1 Formulaire, 4 Groupes Item, 21 Eléments de données, 1 Langue
Groupes Item: Patient Information, Chemotherapy Regimen, Hospitalization, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Study Protocol IB. Clinical Trial Number: NCT01117441.

Protocol IIA AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Protocol IIA AIEOP-BFM ALL 2009 NCT01117441

- 21/05/2016 - 1 Formulaire, 5 Groupes Item, 31 Eléments de données, 1 Langue
Groupes Item: Patient Information, Chemotherapy Regimen, PEG-L-ASP/ Erwinase, Hospitalization, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Study Protocol IIA. Clinical Trial Number: NCT01117441.

Protocol IB AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Protocol IB AIEOP-BFM ALL 2009 NCT01117441

- 21/05/2016 - 1 Formulaire, 4 Groupes Item, 21 Eléments de données, 1 Langue
Groupes Item: Patient Information, Chemotherapy Regimen, Hospitalization, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Study Protocol IB. Clinical Trial Number: NCT01117441.

Protocol IAD AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Protocol IAD AIEOP-BFM ALL 2009 NCT01117441

- 15/05/2016 - 1 Formulaire, 4 Groupes Item, 33 Eléments de données, 1 Langue
Groupes Item: Patient Information, Chemotherapy Regimen, PEG-L-ASP/ Erwinase, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Study Protocol IAD (Study Protocol IA with Dexamethasone). Clinical Trial Number: NCT01117441.

Protocol IIB-ASP+ AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Protocol IIB-ASP+ AIEOP-BFM ALL 2009 NCT01117441

- 21/05/2016 - 1 Formulaire, 5 Groupes Item, 28 Eléments de données, 1 Langue
Groupes Item: Patient Information, Chemotherapy Regimen, PEG-L-ASP discontinuation, Hospitalization, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Study Protocol IIB (Study Protocol IIB with PEG-L-ASP). Clinical Trial Number: NCT01117441.

Protocol IB-ASP+ AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Protocol IB-ASP+ AIEOP-BFM ALL 2009 NCT01117441

- 21/05/2016 - 1 Formulaire, 5 Groupes Item, 33 Eléments de données, 1 Langue
Groupes Item: Patient Information, Chemotherapy Regimen, PEG-L-ASP discontinuation, Hospitalization, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Study Protocol IB (Study Protocol IB with PEG-L-ASP). Clinical Trial Number: NCT01117441.

Protocol IB-ASP+ AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Protocol IB-ASP+ AIEOP-BFM ALL 2009 NCT01117441

- 21/05/2016 - 1 Formulaire, 5 Groupes Item, 28 Eléments de données, 1 Langue
Groupes Item: Patient Information, Chemotherapy Regimen, PEG-L-ASP discontinuation, Hospitalization, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Study Protocol IB (Study Protocol IB with PEG-L-ASP). Clinical Trial Number: NCT01117441.

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial